| Description: | The Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ) is a scale used to assess treatment response or nonresponse to adequate treatment trials among patients with major depressive disorder (MDD).1 The ATRQ examines the adequacy of duration and dose of prior and current antidepressant treatment trials.2 The ATRQ also assesses the degree of improvement in depressive symptoms in the most efficacious trial or in all trials during the current episode.2 The utility of this scale is in allowing a patient-report tool to take the place of a potentially lengthy clinician interview in assessing past antidepressant treatment adequacy and efficacy.1 |
|---|---|
| Disease States: | Major depressive disorder |
| Validated Uses: | Treatment Monitoring & Evaluation |
| Administration Method: | Self-report, Clinician-report |
| Time to administer: | Not applicable. |
| Commonly used in: | Clinical Trials & Research, Clinical Practice |
| Detailed Description: | The MGH ATRQ is a scale used to determine treatment response or nonresponse in patients with MDD.1 This scale examines a patient's antidepressant treatment history, using specific criteria to define the adequacy of both dose and duration of each antidepressant trial, and the degree of symptomatic improvement obtained with each trial.1,4 |
| Scale Validity: | The ATRQ was found to be concordant with independent clinical researchers in its assessment of a patient’s prior response(s) to adequate courses of treatment for depression.1 |
| Alternative Versions: | None |
| Cited Limitations: | The ATRQ may underreport the number of unsuccessful treatment trials.1 |
Footnotes:
This resource is intended for educational purposes only and is intended for US healthcare professionals. Healthcare professionals should use independent medical judgment. All decisions regarding patient care must be handled by a healthcare professional and be made based on the unique needs of each patient.
This is not a diagnostic tool and is not intended to replace a clinical evaluation by a healthcare provider.
ABBV-US-01254-MC, Version 1.0
Approved 04/2023
AbbVie Medical Affairs